

David E Thurston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1452744/publications.pdf>

Version: 2024-02-01

79
papers

3,746
citations

147801

31
h-index

128289

60
g-index

79
all docs

79
docs citations

79
times ranked

2275
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF- κ B activity and synergise with bortezomib and ibrutinib in hematological cancers. <i>Haematologica</i> , 2021, 106, 958-967.	3.5	4
2	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
3	A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. <i>Cancers</i> , 2020, 12, 1029.	3.7	22
4	UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1146, 122075.	2.3	7
5	Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF- κ B Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2127-2139.	6.4	17
6	CHAPTER 1. Introduction to Antibody-Drug Conjugates (ADCs). <i>RSC Drug Discovery Series</i> , 2019, , 1-30.	0.3	12
7	Methylene-linked bis-phenylbenzimidazoles - a new scaffold to target telomeric DNA/RNA hybrid duplex. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 4424-4428.	2.8	3
8	Formation of a Novel C11-Acetone Adduct of a Pyrrolobenzodiazepine (PBD) with Loss of Cytotoxicity. <i>Synlett</i> , 2018, 29, 1112-1116.	1.8	1
9	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). <i>OncImmunology</i> , 2018, 7, e1395127.	4.6	117
10	Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?. <i>Drug Discovery Today: Technologies</i> , 2018, 30, 71-83.	4.0	27
11	Topical delivery of anthramycin II. Influence of binary and ternary solvent systems. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 59-64.	4.0	13
12	Abstract 736: Pyridinobenzodiazepines (PDDs): A new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity. <i>Cancer Research</i> , 2018, 78, 736-736.	0.9	4
13	Topical delivery of anthramycin I. Influence of neat solvents. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 188-195.	4.0	28
14	Sequence-selective binding of C8-conjugated pyrrolobenzodiazepines (PBDs) to DNA. <i>Biophysical Chemistry</i> , 2017, 230, 53-61.	2.8	4
15	Entwicklung Pyrrolobenzodiazepin(PBD)-haltiger Antikörper-Wirkstoff-Konjugate (ADCs) ausgehend von Anthramycin. <i>Angewandte Chemie</i> , 2017, 129, 474-502.	2.0	13
16	From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). <i>Angewandte Chemie - International Edition</i> , 2017, 56, 462-488.	13.8	197
17	Recent advances in targeting the telomeric G-quadruplex DNA sequence with small molecules as a strategy for anticancer therapies. <i>Future Medicinal Chemistry</i> , 2016, 8, 1259-1290.	2.3	56
18	Abstract 4779: In silico design, synthesis and evaluation of a new family of C1-substituted pyrrolobenzodiazepines (PBDs). <i>Cancer Research</i> , 2016, 76, 4779-4779.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments. <i>PLoS ONE</i> , 2016, 11, e0152303.	2.5	13
20	Effect of hairpin loop structure on reactivity, sequence preference and adduct orientation of a DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agent. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 4031-4040.	2.8	9
21	Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. <i>BMC Veterinary Research</i> , 2015, 11, 215.	1.9	8
22	Pyrrolobenzodiazepines (PBDs) Do Not Bind to DNA G-Quadruplexes. <i>PLoS ONE</i> , 2014, 9, e105021.	2.5	10
23	Computational Studies Support the Role of the C7-Sibirosamine Sugar of the Pyrrolobenzodiazepine (PBD) Sibiromycin in Transcription Factor Inhibition. <i>ACS Chemical Biology</i> , 2014, 9, 2432-2440.	3.4	15
24	Abstract 5329: Molecular dynamics simulations of sibiromycin suggest a role for the c7-sugar in transcription factor inhibition. <i>Cancer Research</i> , 2014, 74, 5329-5329.	0.9	3
25	Abstract 5370: Use of molecular dynamics simulations to rationalise the DNA sequence-selectivity of pyrrolobenzodiazepine-MPB conjugates. <i>Cancer Research</i> , 2014, 74, 5370-5370.	0.9	4
26	An Extended Pyrrolobenzodiazepine Polyamide Conjugate with Selectivity for a DNA Sequence Containing the ICB2 Transcription Factor Binding Site. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6339-6351.	6.4	30
27	A Potent Anti-CD70 Antibody Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology. <i>Bioconjugate Chemistry</i> , 2013, 24, 1256-1263.	3.6	226
28	GC-Targeted C8-Linked Pyrrolobenzodiazepine Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2911-2935.	6.4	50
29	Abstract 1129: GC-t8-linked pyrrolobenzodiazepine (PBD)-biaryl conjugates with femptomolar in vitro cytotoxicity and in vivo antitumour activity in mouse models of pancreatic and breast cancer. <i>Cancer Research</i> , 2013, 73, 1129-1129.	0.9	5
30	Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1683-1696.	3.0	23
31	The prenylated dioxopiperazine alkaloid Cristatin A has selective telomeric DNA G-quadruplex stabilising properties. <i>Chemical Communications</i> , 2012, 48, 8760.	4.1	7
32	DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. <i>Investigational New Drugs</i> , 2012, 30, 950-958.	2.6	31
33	Identification of novel telomeric G-quadruplex-targeting chemical scaffolds through screening of three NCI libraries. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3006-3010.	2.2	29
34	Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs). <i>Chemical Reviews</i> , 2011, 111, 2815-2864.	47.7	173
35	Observation of a Single-Stranded DNA/Pyrrolobenzodiazepine Adduct. <i>Journal of the American Chemical Society</i> , 2011, 133, 19376-19385.	13.7	26
36	Observation of the reversibility of a covalent pyrrolobenzodiazepine (PBD) DNA adduct by HPLC/MS and CD spectroscopy. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 1632.	2.8	26

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 777-786.	2.3	10
38	Novel C8-linked pyrrolobenzodiazepine (PBD) heterocycle conjugates that recognize DNA sequences containing an inverted CCAAT box. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3780-3783.	2.2	19
39	Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers. <i>Nucleic Acids Research</i> , 2011, 39, 5800-5812.	14.5	38
40	The minor groove-binding agent ELB-21 forms multiple interstrand and intrastrand covalent cross-links with duplex DNA and displays potent bactericidal activity against methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 985-996.	3.0	16
41	SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity. <i>Cancer Research</i> , 2010, 70, 6849-6858.	0.9	55
42	DNA Sequence Preference and Adduct Orientation of Pyrrolo[2,1-c][1,4]benzodiazepine Antitumor Agents. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 427-432.	2.8	36
43	Biaryl polyamides as a new class of DNA quadruplex-binding ligands. <i>Chemical Communications</i> , 2009, , 4097.	4.1	40
44	The Pyrrolobenzodiazepine Dimer SJG-136 Forms Sequence-Dependent Intrastrand DNA Cross-Links and Monoalkylated Adducts in Addition to Interstrand Cross-Links. <i>Journal of the American Chemical Society</i> , 2009, 131, 13756-13766.	13.7	69
45	Observation of a dynamic equilibrium between DNA hairpin and duplex forms of covalent adducts of a minor groove binding agent. <i>Chemical Communications</i> , 2009, , 227-229.	4.1	13
46	Welcome to Future Medicinal Chemistry. <i>Future Medicinal Chemistry</i> , 2009, 1, 1-2.	2.3	4
47	Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: Synthesis, DNA interaction, cytotoxicity and differential cellular localization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2147-2151.	2.2	29
48	An assay combining high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences. <i>Analytical Biochemistry</i> , 2008, 374, 173-181.	2.4	21
49	Inhibition of DNA binding of the NF- κ B transcription factor by the pyrrolobenzodiazepine-polyamide conjugate CWL-78. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1319-1328.	4.1	52
50	Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. <i>British Journal of Cancer</i> , 2007, 97, 253-259.	6.4	20
51	Synthesis of a novel C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione library: Effect of C2-aryl substitution on cytotoxicity and non-covalent DNA binding. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3041-3053.	3.0	31
52	Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine-Poly(N-methylpyrrole) Conjugates. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5442-5461.	6.4	70
53	Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1602-1609.	4.1	16
54	The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. <i>Nucleic Acids Research</i> , 2005, 33, 3283-3291.	14.5	65

#	ARTICLE	IF	CITATIONS
55	Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 822, 10-20.	2.3	11
56	Pyrrlobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 513-518.	3.0	29
57	Sequence-Selective Interaction of the Minor-Groove Interstrand Cross-Linking Agent SJG-136 with Naked and Cellular DNA: Footprinting and Enzyme Inhibition Studies. <i>Biochemistry</i> , 2005, 44, 4135-4147.	2.5	44
58	Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrlobenzodiazepine dimer SJG-136. <i>European Journal of Cancer</i> , 2005, 41, 1811-1818.	2.8	23
59	SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity. <i>Cancer Research</i> , 2004, 64, 6700-6706.	0.9	82
60	SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity. <i>Cancer Research</i> , 2004, 64, 6693-6699.	0.9	123
61	Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrlobenzodiazepine dimer DNA-cross-linking agent. <i>Investigational New Drugs</i> , 2004, 22, 231-240.	2.6	20
62	Linker Length Modulates DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8 Ether-Linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1161-1174.	6.4	93
63	Synthesis of the first examples of A-C8/C-C2 amide-Linked pyrrolo[2,1-c][1,4]benzodiazepine dimers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2277-2280.	2.2	22
64	Sequence-Selective Recognition of Duplex DNA through Covalent Interstrand Cross-Linking: Kinetic and Molecular Modeling Studies with Pyrrlobenzodiazepine Dimers. <i>Biochemistry</i> , 2003, 42, 8232-8239.	2.5	57
65	Design, Synthesis, and Evaluation of a Novel Pyrrlobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 737-748.	6.4	187
66	Effect of A-Ring Modifications on the DNA-Binding Behavior and Cytotoxicity of Pyrrolo[2,1-c][1,4]benzodiazepines. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1951-1964.	6.4	87
67	Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5131-5141.	6.4	64
68	Inhibition of Bacteriophage T7 RNA Polymerase in Vitro Transcription by DNA-Binding Pyrrolo[2,1-c][1,4]benzodiazepines. <i>Biochemistry</i> , 1997, 36, 2478-2484.	2.5	88
69	Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 431-438.	2.3	28
70	Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines. <i>Chemical Reviews</i> , 1994, 94, 433-465.	47.7	270
71	Structure of a Covalent DNA Minor Groove Adduct with a Pyrrlobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand Crosslinking. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 4529-4537.	6.4	87
72	A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics based on the inhibition of restriction endonuclease BamHI. <i>Nucleic Acids Research</i> , 1993, 21, 3671-3675.	14.5	78

#	ARTICLE	IF	CITATIONS
73	Advances in the Study of Pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) Antitumour Antibiotics. , 1993, , 54-88.		75
74	Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. Journal of the American Chemical Society, 1992, 114, 4939-4941.	13.7	147
75	Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers. Journal of the Chemical Society Chemical Communications, 1992, , 1518.	2.0	68
76	Evaluation of the electrophilicity of DNA-binding pyrrolo(2,1-c)(1,4)benzodiazepines by HPLC.. Journal of Antibiotics, 1990, 43, 1286-1292.	2.0	30
77	Synthesis and reactivity of a novel oxazolo[2, 3-c][1,4]benzodiazepine ring system with DNA recognition potential: a new class of anthramycins. Journal of the Chemical Society Chemical Communications, 1990, , 874.	2.0	19
78	Pyrrolo[1,4]benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chemical Research in Toxicology, 1988, 1, 258-268.	3.3	144
79	Pyrrolo[1,4]benzodiazepine antitumor antibiotics: evidence for two forms of tomaymycin bound to DNA. Biochemistry, 1986, 25, 3021-3031.	2.5	50